There are some data which could suggest that once anti-VEGF treatment is used in a first or second line regimen, it would not be as effective when used again in later line regimens, because resistance towards cancer drugs, including anti-VEGF inhibitors, is a common concern [24, 25]. The gene discussed is VEGFA; the disease is cancer.